The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Sponsor
The George Institute
Study ID
NCT06058585
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Kidney Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Finerenone — DRUG
    Finerenone 10mg or 20mg tablets, oral, once daily
  • Placebo Finerenone — DRUG
    Finerenone matched placebo tablets, oral, once daily

Study Details

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD). CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure. CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

Key Dates

Start date
Sep 4, 2024
Status verified
May 2025
Primary completion
Aug 30, 2028
Completion
Mar 31, 2029

Study Design

Enrollment
1,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Finerenone
    Finerenone 10mg or 20mg tablets
  • Placebo Comparator: Placebo Finerenone
    Finerenone matched placebo tablets

Primary Outcome Measure

eGFR slope [ Time Frame: From randomisation to week 108 ]

Central Contacts

Related Studies